Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT01649778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course of an enrollment period of approximately 18 months.There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 30 months or until premature discontinuation (i.e., due to death, withdrawal of consent, lost to follow-up or study termination).
Study identification
- NCT ID
- NCT01649778
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 662 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 18, 2012
- Primary completion
- Jul 2, 2017
- Completion
- Jul 2, 2017
- Last update posted
- Jul 14, 2020
2012 – 2017
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85016 | — |
| Novartis Investigative Site | Orange | California | 92868 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32256 | — |
| Novartis Investigative Site | Louisville | Kentucky | 40207 | — |
| Novartis Investigative Site | Shreveport | Louisiana | 71101 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39202 | — |
| Novartis Investigative Site | Lincoln | Nebraska | 68510 | — |
| Novartis Investigative Site | Henderson | Nevada | 89052 | — |
| Novartis Investigative Site | The Bronx | New York | 10467 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29414 | — |
| Novartis Investigative Site | Sioux Falls | South Dakota | 57105 | — |
| Novartis Investigative Site | Austin | Texas | 78705 | — |
| Novartis Investigative Site | Dallas | Texas | 75246 | — |
| Novartis Investigative Site | Fort Worth | Texas | 76104 | — |
| Novartis Investigative Site | Houston | Texas | 77024 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01649778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2020 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01649778 live on ClinicalTrials.gov.